Bonti, Inc.

AbbVie Inc. will keep Allergan PLC ’s market-leading medical aesthetics business in the hands of Allergan employees who know how to develop and market products in this unique biopharmaceutical and m

AbbVie Inc. CEO Richard Gonzalez said repeatedly when describing the company's rationale for buying Allergan PLC for $63bn that very little value was ascribed to Allergan's research and development

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmace

Jonathan Lim's latest start-up Erasca was established this year to develop "precision oncology" drugs designed to erase cancer, but while the firm was able to entice venture capital investors with e